18 May 2022
Transparency notification Wellington
Read More
13 May 2022
13 May 2022
Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab
Read More
10 May 2022
UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis
Read More
2 May 2022
JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA[®]▼(fenfluramine) Oral Solution for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS)
Read More
28 Apr 2022
UCB’s General Meeting of Shareholders 2022
Read More
